https://doi.org/10.18502/ijrm.v17i3.4519
statistics
- 221 Abstract Views
- 132 PDF Views
- 0 HTML Views
- Cited by 5 articles
authors
-
Zohreh Rahimi
No author data available.
-
Ehsan Mohammadi
No author data available.
Published Date
- May 29, 2019
The CYP17 MSP AI (T-34C) and CYP19A1 (Trp39Arg) variants in polycystic ovary syndrome: A case-control study
Abstract
Background: Polycystic ovary syndrome (PCOS) is a common and chronic disorder of endocrine glands where genetic factors play a major role in the susceptibility to the disease. The cytochrome (CYP) 17 enzyme is essential for androgens biosynthesis. Also, the CYP19 enzyme converts the androgens to the aromatic estrogens.
Objective: We aimed to investigate the association of CYP 17 MSP AI (T-34C) and CYP 19A1 (Trp39Arg) variants with the pathogenesis of PCOS in a population from Western Iran with Kurdish ethnic background.
Materials and Methods: The present case-control study consisted of 50 patients with PCOS and 109 controls. The CYP17 T-34C and CYP19A1 (Trp39Arg) polymorphisms were identified by polymerase chain reaction-restriction fragment length polymorphism. The serum lipid and lipoprotein profile were detected by the Bionic Diagnostic Kits. Estradiol, dehydroepiandrosterone (DHEA), and sex hormone-binding globulin (SHBG) levels were measured using the chemiluminescent method.
Results: The serum levels of estradiol and SHBG in PCOS patients were lower than controls (p < 0.001 and p =0.06, respectively). However, the level of DHEA was higher (p= 0.01) in patients compared to controls. The higher frequency of CYP17 TC genotype in patients (30%) compared to controls (15.6%) was associated with 2.31-fold susceptibility to PCOS (p = 0.038). The frequency of CYP19 TC genotype was 6.4% in controls and
10% in patients (p = 0.42).
Conclusion: The present study suggests that CYP17 TC genotype could be associated with the risk of PCOS. Also, the study indicated the sex steroid hormones level alteration and the lower level of SHBG in PCOS patients compared to healthy individuals.
References
diagnosis. Nat Rev Endocrinol 2011; 7: 219–231.
[2] Fenichel P, Rougier C, Hieronimus S, Chevalier N. Which origin for polycystic ovaries syndrome: Genetic, environmental or both? Ann Endocrinol (Paris) 2017; 78: 176–185.
[3] Moore AM, Campbell RE. Polycystic ovary syndrome: understanding the role of the brain. Front Neuroendocrinol 2017; 46: 1–14.
[4] Kumar AN, Naidu JN, Satyanarayana U, Ramalingam K, Anitha M. Metabolic and endocrine characteristics of
Indian women with polycystic ovary syndrome. Int J Fertil Steril 2016; 10: 22–28.
[5] Li L, Gu ZP, Bo QM, Wang D, Yang XS, Cai GH. Association of CYP17A1 gene-34T/C polymorphism with polycystic ovary syndrome in Han Chinese population. Gynecol Endocrinol 2015; 31: 40–43.
[6] Li Y, Liu F, Luo S, Hu H, Li XH, Li SW. Polymorphism T→ C of gene CYP17 promoter and polycystic ovary syndrome risk: a meta-analysis. Gene 2012; 495: 16–22.
[7] Panda PK, Rane R, Ravichandran R, Singh S, Panchal H. Genetics of PCOS: a systematic bioinformatics approach to unveil the proteins responsible for PCOS. Genom Data 2016; 8: 52–60.
[8] Unsal T, Konac E, Yesilkaya E, Yilmaz A, Bideci A, Onen HI, et al. Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome. J Assist Reprod Genet 2009; 26: 205–216.
[9] Ramos Cirilo PD, Rosa FE, Moreira Ferraz MF, Rainho CA, Pontes A, Rogatto SR. Genetic polymorphisms associated with steroids metabolism and insulin action in polycystic ovary syndrome. Gynecol Endocrinol 2012; 28: 190–194.
[10] Lin L, Ercan O, Raza J, Burren CP, Creighton SM, Auchus RJ, et al. Variable phenotypes associated with aromatase (CYP19) insufficiency in humans. J Clin Endocrinol Metab 2007; 92: 982–990.
[11] Surekha D, Sailaja K, Rao DN, Padma T, Raghunadharao D, Vishnupriya S. Association of CYP19 polymorphisms with breast cancer risk: A case-control study. J Nat Sci Biol Med 2014; 5: 250–254.
[12] Wang L, Lu X, Wang D, Qu W, Li W, Xu X, et al. CYP19 gene variant confers susceptibility to endometriosis-associated infertility in Chinese women. Exp Mol Med 2014; 46: e103– e109.
[13] Nativelle-Serpentini C, Lambard S, Seralini GE, Sourdaine P. Aromatase and breast cancer: W39R, an inactive protein. Eur J Endocrinol 2002; 146: 583–589.
[14] Hanash-Dhefer I, Abdul-Rudha Abbas S, Ahmed SH N. Polymorphism of cytochrome p450, superfamily19,
polypeptide 1 gene and related to aromatase enzyme activity in acromegaly Iraqi patients. Asian J Pharm Clin
Res 2017; 10: 228–232.
[15] Zettergren A, Jonsson L, Johansson D, Melke J, Lundström S, Anckarsäter H, et al. Associations between polymorphisms in sex steroid related genes and autistic-like traits. Psychoneuroendocrinology 2013; 38: 2575–2584.
[16] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–47.
[17] Jafari Y, Rahimi Z, Vaisi-Raygani A, Rezaei M. Interaction of eNOS polymorphism with MTHFR variants increase the risk of diabetic nephropathy and its progression in type 2 diabetes mellitus patients. Mol Cell Biochem 2011; 353:23–34.
[18] Han QH, Shan ZJ, Hu JT, Zhang N, Zhang XP. Relationship between gene polymorphisms and prostate cancer risk. Asian Pac J Trop Med 2015; 8: 569–573.
[19] Hirose K, Matsuo K, Toyama T, Iwata H, Hamajima N, Tajima K. The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese. Cancer Epidemiol Biomarkers
Prev 2004; 13: 1407–1411.
[20] Chamaie-Nejad F, Saeidi S, Najafi F, Ebrahimi A, Rahimi Z, Shakiba E, et al. Association of the CYP17 MSP AI (T34C) and CYP19 codon 39 (Trp/Arg) polymorphisms with susceptibility to acne vulgaris. Clin Exp Dermatol 2018; 43:183–186.
[21] Diamanti-Kandarakis E, Bartzis MI, Zapanti ED, Spina GG, Filandra FA, Tsianateli TC, et al. Polymorphism T–> C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril 1999; 71: 431–435.
[22] Marszalek B, Laciński M, Babych N, Capla E, BiernackaLukanty J, Warenik-Szymankiewicz A, et al. Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5′-UTR in patients with polycystic ovarian syndrome. Gynecol Endocrinol 2001; 15: 123–128.
[23] Pusalkar M, Meherji P, Gokral J, Chinnaraj S, Maitra A. CYP11A1 and CYP17 promoter polymorphisms associate with hyperandrogenemia in polycystic ovary syndrome. Fertil Steril 2009; 92: 653–659.
[24] Techatraisak K, Conway GS, Rumsby G. Frequency of a polymorphism in the regulatory region of the 17 alphahydroxylase-17, 20-lyase (CYP17) gene in hyperandrogenic states. Clin Endocrinol (Oxf) 1997; 46: 131–134.
[25] Park JM, Lee EJ, Ramakrishna S, Cha DH, Baek KH. Association study for single nucleotide polymorphisms in
the CYP17A1 gene and polycystic ovary syndrome. Int J Mol Med 2008; 22: 249–254.
[26] Piller R, Verla-Tebit E, Wang-Gohrke S, Linseisen J, ChangClaude J. CYP17 genotype modifies the association
between lignan supply and premenopausal breast cancer risk in humans. J Nutr 2006; 136: 1596–1603.
[27] Ambrosone CB, Moysich KB, Furberg H, Freudenheim JL, Bowman ED, Ahmed S, et al. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res 2003; 5: R45–51.
[28] Mehdizadeh A, Kalantar SM, Sheikhha MH, Aali BS, Ghanei A. Association of SNP rs.2414096 CYP19 gene
with polycystic ovarian syndrome in Iranian women. Int J Reprod Biomed (Yazd) 2017; 15: 491–496.
[29] Kiranmayee D, Kavya K, Himabindu Y, Sriharibabu M, Madhuri GLJ, Venu S. Correlations between anthropometryand lipid profile in women with PCOS. J Hum Reprod Sci 2017; 10: 167–172.